Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

This week several key companies are set to release earnings, giving markets some insight into their performance and future ...